Skip to main content
Top
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors

Authors: Rui-qing Liu, Shu-jing Shen, Xiu-feng Hu, Jie Liu, Li-juan Chen, Xing-ya Li

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Aim

The incidence and mortality associated with intrahepatic cholangiocarcinoma is increasing in many countries and documentation of disease outcome is sparse. The present study was undertaken to investigate the prognostic factors for intrahepatic cholangiocarcinoma (ICC) following surgical resection. The impact of pre-existing HBV virus infection and adjuvant chemotherapy on the overall survival was also evaluated.

Methods

Clinical and pathological data were collected retrospectively from 81 patients undergoing surgery for ICC between 2005 and 2011, at The Henan Province Tumor Hospital and the First Affiliated Hospital of Zheng Zhou University. Survival and prognosis were analyzed using the Kaplan-Meier method and COX regression model.

Results

The population included 37 patients who were HBsAg + or anti-HBc+, 21 patients who were anti-HBs + positive and 18 patients who received adjuvant chemotherapy. The overall 1- and 3-year survival rates were 51% and 20%, respectively. The median survival was 12.2 months. Univariate analysis identified the following prognostic factors: HBV virus infection or HBV vaccine prior to resection (P = 0.017); adjuvant chemotherapy (P = 0.001); preoperative serum CA19-9 (> 200 U/mL; P = 0.015); GGT (> 64 U/L; P = 0.008), ALP (> 119 U/L; P = 0.01); lymph node metastasis (P = 0.005); radical resection (P = 0.021); intrahepatic metastasis (P = 0.015) and diabetes (P = 0.07). Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors.

Conclusions

HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ikai I, Itai Y, Okita K: Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004, 28 (1): 21-29. 10.1016/j.hepres.2003.08.002.CrossRefPubMed Ikai I, Itai Y, Okita K: Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004, 28 (1): 21-29. 10.1016/j.hepres.2003.08.002.CrossRefPubMed
2.
go back to reference Khan SA, Thomas HC, Davidson BR: Cholangiocarcinoma. Lancet. 2005, 366 (9493): 1303-1310. 10.1016/S0140-6736(05)67530-7.CrossRefPubMed Khan SA, Thomas HC, Davidson BR: Cholangiocarcinoma. Lancet. 2005, 366 (9493): 1303-1310. 10.1016/S0140-6736(05)67530-7.CrossRefPubMed
3.
go back to reference Wang W-l, Guang-yu G, Min H: Expressionandsignificance of hepatitis Bvirus genes inhumanprimaryintrahepatic cholangiocar-cinomaanditssurroundingtissue. Chin J Oncol. 1996, 18 (2): 127-129. Wang W-l, Guang-yu G, Min H: Expressionandsignificance of hepatitis Bvirus genes inhumanprimaryintrahepatic cholangiocar-cinomaanditssurroundingtissue. Chin J Oncol. 1996, 18 (2): 127-129.
4.
go back to reference Qu ZL, Zou SQ, Cui NQ: Upregulation of human telomerase reverse transcriptase mRNA expression by in vitrotransfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells. World J Gastroenterol. 2005, 11 (36): 5627-5632.PubMedCentralPubMed Qu ZL, Zou SQ, Cui NQ: Upregulation of human telomerase reverse transcriptase mRNA expression by in vitrotransfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells. World J Gastroenterol. 2005, 11 (36): 5627-5632.PubMedCentralPubMed
5.
go back to reference Zhang L, Cai JQ, Zhao JJ: Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2010, 101 (3): 233-238. 10.1002/jso.21488.CrossRefPubMed Zhang L, Cai JQ, Zhao JJ: Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2010, 101 (3): 233-238. 10.1002/jso.21488.CrossRefPubMed
6.
go back to reference Zhou HB, Wang H, Li YQ: Hepatitis B virus infection: A favorable prognostic factor for intrahepatic cholangiocarcinoma after resection. World J Gastroenterol. 2011, 17 (10): 1292-1303. 10.3748/wjg.v17.i10.1292.PubMedCentralCrossRefPubMed Zhou HB, Wang H, Li YQ: Hepatitis B virus infection: A favorable prognostic factor for intrahepatic cholangiocarcinoma after resection. World J Gastroenterol. 2011, 17 (10): 1292-1303. 10.3748/wjg.v17.i10.1292.PubMedCentralCrossRefPubMed
7.
go back to reference Vitale F, Tramuto F, Orlando A: Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection. J Med Virol. 2008, 80 (4): 577-582. 10.1002/jmv.21121.CrossRefPubMed Vitale F, Tramuto F, Orlando A: Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection. J Med Virol. 2008, 80 (4): 577-582. 10.1002/jmv.21121.CrossRefPubMed
8.
go back to reference Arase Y, Suzuki F, Suzuki Y: Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology. 2007, 50 (3): 161-165. 10.1159/000098958.CrossRefPubMed Arase Y, Suzuki F, Suzuki Y: Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology. 2007, 50 (3): 161-165. 10.1159/000098958.CrossRefPubMed
9.
go back to reference Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005, 16 (2): ii93-ii96.CrossRefPubMed Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005, 16 (2): ii93-ii96.CrossRefPubMed
10.
go back to reference Yue M, Ying-Chun X, Lei T: Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol & Oncol. 2012, 1: 11-10.1186/2162-3619-1-11.CrossRef Yue M, Ying-Chun X, Lei T: Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol & Oncol. 2012, 1: 11-10.1186/2162-3619-1-11.CrossRef
11.
go back to reference Chen LP, Li C, Wang C: Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology. 2012, 59 (118): 1765-1768.PubMed Chen LP, Li C, Wang C: Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology. 2012, 59 (118): 1765-1768.PubMed
12.
go back to reference Nanashima A, Sumida Y, Abo T: Relationship between pattern of tumor enhancement and clinicopathologic characteristics in intrahepatic cholangiocarcinoma. J Surg Oncol. 2008, 98 (7): 535-539. 10.1002/jso.21142.CrossRefPubMed Nanashima A, Sumida Y, Abo T: Relationship between pattern of tumor enhancement and clinicopathologic characteristics in intrahepatic cholangiocarcinoma. J Surg Oncol. 2008, 98 (7): 535-539. 10.1002/jso.21142.CrossRefPubMed
13.
go back to reference Haruna Y, Saito K, Spaulding S: Identification of bipotential progenitor cells in human liver development. Hepatology. 1996, 23 (3): 476-481. 10.1002/hep.510230312.CrossRefPubMed Haruna Y, Saito K, Spaulding S: Identification of bipotential progenitor cells in human liver development. Hepatology. 1996, 23 (3): 476-481. 10.1002/hep.510230312.CrossRefPubMed
14.
go back to reference Ding F-x, Wang F, Yi-ming L: Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus–related hepatocellular carcinoma. Hepatology. 2009, 49 (5): 1492-1502. 10.1002/hep.22816.CrossRefPubMed Ding F-x, Wang F, Yi-ming L: Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus–related hepatocellular carcinoma. Hepatology. 2009, 49 (5): 1492-1502. 10.1002/hep.22816.CrossRefPubMed
15.
go back to reference Morise Z, Sugioka A, Tokoro T: Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010, 2 (2): 58-64.PubMedCentralPubMed Morise Z, Sugioka A, Tokoro T: Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010, 2 (2): 58-64.PubMedCentralPubMed
16.
go back to reference Li F-H, Chen X-Q, Luo Y-H: Prognosis of 84 intrahepatic cholangiocarcinoam patients. Chin J Cancer. 2009, 28 (5): 528-532. Li F-H, Chen X-Q, Luo Y-H: Prognosis of 84 intrahepatic cholangiocarcinoam patients. Chin J Cancer. 2009, 28 (5): 528-532.
17.
go back to reference Jan YY, Yeh CN, Yeh TS: Prognostic analysis of surgical treatment of periheral cholangiocarcinoma: two decades of experience at chang gung memorial hospital. World J Gas-troenterol. 2005, 11 (12): 1779-1784.CrossRef Jan YY, Yeh CN, Yeh TS: Prognostic analysis of surgical treatment of periheral cholangiocarcinoma: two decades of experience at chang gung memorial hospital. World J Gas-troenterol. 2005, 11 (12): 1779-1784.CrossRef
18.
go back to reference Patel AH, Harnois DM, Klee GG: The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000, 95 (1): 204-207. 10.1111/j.1572-0241.2000.01685.x.CrossRefPubMed Patel AH, Harnois DM, Klee GG: The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000, 95 (1): 204-207. 10.1111/j.1572-0241.2000.01685.x.CrossRefPubMed
19.
go back to reference Ohtsuka M, Ito H, Kimura F: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002, 89 (12): 1525-1531. 10.1046/j.1365-2168.2002.02268.x.CrossRefPubMed Ohtsuka M, Ito H, Kimura F: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002, 89 (12): 1525-1531. 10.1046/j.1365-2168.2002.02268.x.CrossRefPubMed
20.
go back to reference Cho SY, Park SJ, Kim SH: Survival analysis of intrahepatic cholangiocarcinoam after resection. Ann Surg Oncol. 2010, 17 (7): 1823-1830. 10.1245/s10434-010-0938-y.CrossRefPubMed Cho SY, Park SJ, Kim SH: Survival analysis of intrahepatic cholangiocarcinoam after resection. Ann Surg Oncol. 2010, 17 (7): 1823-1830. 10.1245/s10434-010-0938-y.CrossRefPubMed
21.
go back to reference Nathan H, Aloia TA, Vauthey J-N: A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009, 16 (1): 14-22. 10.1245/s10434-008-0180-z.CrossRefPubMed Nathan H, Aloia TA, Vauthey J-N: A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009, 16 (1): 14-22. 10.1245/s10434-008-0180-z.CrossRefPubMed
22.
go back to reference Uenishi T, Yamazaki O, Yamamoto T: Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Surg. 2005, 12 (6): 479-483. 10.1007/s00534-005-1026-8.CrossRef Uenishi T, Yamazaki O, Yamamoto T: Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Surg. 2005, 12 (6): 479-483. 10.1007/s00534-005-1026-8.CrossRef
23.
go back to reference Li HY, Zhou SJ, Li M: Diagnosis and cure experience of hepatolithiasis- associated intrahepatic cholangiocarcinoma in 66 patients. Asian Pac J Cancer Prev. 2012, 13 (2): 725-729. 10.7314/APJCP.2012.13.2.725.CrossRefPubMed Li HY, Zhou SJ, Li M: Diagnosis and cure experience of hepatolithiasis- associated intrahepatic cholangiocarcinoma in 66 patients. Asian Pac J Cancer Prev. 2012, 13 (2): 725-729. 10.7314/APJCP.2012.13.2.725.CrossRefPubMed
24.
go back to reference Zhao S-b, Cai-de L: Dignosis and treatment hepatolithias associated with cholangiocarcinoma:a report of 28 cases. Int J Surg. 2010, 7 (37): 445-447. Zhao S-b, Cai-de L: Dignosis and treatment hepatolithias associated with cholangiocarcinoma:a report of 28 cases. Int J Surg. 2010, 7 (37): 445-447.
25.
go back to reference Chun-xing L, Zhou J: Association between diabetes mellitus and the risk of extrahepatic cholangiocarcinoma: a Meta-analysis. Actauniversitats Medicinalis Nedicinalis Nanjing (Natural Science). 2011, 6 (31): 834-837. Chun-xing L, Zhou J: Association between diabetes mellitus and the risk of extrahepatic cholangiocarcinoma: a Meta-analysis. Actauniversitats Medicinalis Nedicinalis Nanjing (Natural Science). 2011, 6 (31): 834-837.
Metadata
Title
Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors
Authors
Rui-qing Liu
Shu-jing Shen
Xiu-feng Hu
Jie Liu
Li-juan Chen
Xing-ya Li
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-99

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine